Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pfizer Inc. filings document the financial, governance, capital-structure, and material-event disclosures of a global biopharmaceutical company. The company's 8-K reports include quarterly operating results, financial guidance updates, Regulation FD disclosures, clinical or regulatory disclosure categories, material agreements, and other corporate events tied to its medicines, vaccines, pipeline, and commercial organization.
Pfizer's proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, shareholder voting results, and equity-plan governance. Its capital markets filings and 8-K exhibits also disclose common stock, NYSE-listed notes, shelf registration activity, public debt offerings, note maturities, and related capital-structure terms.
Pfizer Inc. executive Christoffel Boshoff reported a tax‑related share withholding tied to equity compensation. On January 30, 2026, 12,887 shares of Pfizer common stock were withheld at $26.44 per share to satisfy tax obligations upon vesting of restricted stock units, rather than being an open‑market sale. After this transaction, Boshoff beneficially owned 155,645 shares directly and 698 shares indirectly through a Rule 16b‑3 plan.
Pfizer Inc. Chairman and CEO Albert Bourla reported an acquisition of 79 Phantom Stock Units SSP on January 14, 2026 at $25.58 per unit. Each unit represents one phantom share of Pfizer common stock and is part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. After this transaction, Bourla held 743,136 phantom stock units. These units are settled in cash after his separation from service and can be moved into an alternative investment account at any time, so they function as deferred cash-based compensation rather than actual shares.
Pfizer Inc. director Mortimer J. Buckley reported a deferred compensation transaction involving phantom stock units tied to Pfizer common stock. On 12/31/2025, he acquired 1,506.024 phantom stock units, each representing one phantom share of common stock. These units reflect deferred director compensation, including dividend equivalents, and are designed to be settled in cash or Pfizer common stock at the director’s election after he retires from the Board of Directors. Following this transaction, Buckley beneficially owned a total of 15,078.063 phantom stock units, all held as a direct interest.
Pfizer Inc. director reports additional deferred compensation units
A Pfizer Inc. director reported acquiring 1,857.43 phantom stock units linked to Pfizer common stock on 12/31/2025. Each unit represents one phantom share of common stock. After this transaction, the director beneficially owns 149,314.146 derivative securities in the form of phantom stock units.
These units represent deferred director compensation, including dividend equivalents, that will be settled in either cash or Pfizer common stock at the director’s election after retirement from the Board of Directors.
Pfizer Inc director Shantanu Narayen reported acquiring 2,008.032 phantom stock units on Pfizer common stock as of 12/31/2025. Each unit represents one phantom share of common stock tied to deferred director compensation, including dividend equivalents.
These units are to be settled in cash or common stock at the director's election after retirement from the Board of Directors. Following this transaction, Narayen beneficially owned 183,164.359 derivative securities related to Pfizer common stock, recorded at a derivative security price of $24.9.
Pfizer Inc. director reports phantom stock unit grant tied to board compensation. On 12/31/2025, a reporting person serving as a Pfizer director acquired 1,556.225 phantom stock units linked to Pfizer common stock at a price of $24.9 per unit. These units represent deferred director compensation, including dividend equivalents, that can be settled in cash or Pfizer common stock at the director's election after retiring from the Board of Directors. Following this transaction, the director beneficially owned 74,697.055 derivative securities in the form of phantom stock units, held directly.
Pfizer Inc. director reports additional deferred compensation in phantom stock units. On 12/31/2025, director James C. Smith acquired 1,807.229 phantom stock units tied to Pfizer common stock at a derivative security price of $24.9. After this transaction, he beneficially owned 166,119.84 derivative securities directly.
Each phantom stock unit represents one phantom share of Pfizer common stock. These units reflect deferred director compensation, including dividend equivalents, and will be settled in cash or common stock at the director’s election after he retires from the Board of Directors. The filing reports an acquisition of compensation-linked units rather than an open-market stock sale.
Pfizer Inc. director compensation update: A Pfizer Inc. (PFE) director reported receiving 1,506.024 phantom stock units on 12/31/2025 as part of deferred director compensation. Each unit represents one phantom share of common stock, with the units to be settled in cash or common stock at the director's election following retirement from the Board of Directors. After this transaction, the director beneficially owned 25,349.741 phantom stock units, held in direct form.
Pfizer Inc. Chairman and CEO Albert Bourla, who also serves as a director of Pfizer Inc. (PFE), reported a routine change in his deferred compensation holdings as of 12/31/2025. The filing shows the acquisition of 24 Phantom Stock Units SSP, a type of derivative security that tracks Pfizer common stock.
Each phantom unit represents one phantom share of Pfizer common stock and is part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. These units are settled in cash after Bourla’s separation from service and may be moved into an alternative investment account at any time. Following this transaction, he beneficially owns 743,147 derivative securities related to these phantom stock units on a direct basis.
Pfizer Inc. Chairman and CEO Albert Bourla reported acquiring 23 phantom stock units linked to Pfizer common stock on 12/15/2025 under a deferred compensation plan.
Each unit represents one phantom share and is settled in cash after his separation from service. Following this transaction, Bourla beneficially owned 742,986 phantom stock units directly.